2EF demonstrated the capability to bind to Trop2 at cell-cell junctions in MCF-7 breast cancer cells, and at deeply located sites in prostate cancer previously inaccessible to other anti-Trop-2 antibodies (T16). Here, TACSTD2 is linked to breast carcinoma.